Cipla Shares Rally 8% Despite 55% YoY Slump in Q4 Profit: Why Citi, Nuvama, and Other Brokerages Hiked Target

Introduction to Cipla's Q4 Performance

Cipla shares rallied 8% on Thursday, despite reporting a 55% year-over-year (YoY) slump in Q4 profit. The stock hit an intraday high of ₹1,432.10 as investors focused on future growth prospects over near-term earnings pressure. This surge in Cipla's shares extends the gains to nearly 11% in two sessions.

Q4 Earnings Overview

Cipla's Q4 net profit declined by 55% YoY, which is a significant drop. However, several brokerages, including Citi and Nuvama, have turned bullish on the stock, citing future growth prospects. The company's revenue and earnings before interest, tax, depreciation, and amortization (EBITDA) also declined, but the brokerages believe that the worst is behind Cipla.

Brokerages' Target Price Hike

Citi, Nuvama, and other brokerages have hiked their target price for Cipla, despite the weak Q4 performance. Citi has raised its target price to ₹1,550, while Nuvama has increased its target to ₹1,600. Other brokerages, such as Motilal Oswal and ICICI Securities, have also turned bullish on the stock, citing the company's strong product pipeline and improving operational efficiency.

Future Growth Prospects

Cipla's future growth prospects are driven by its strong product pipeline, particularly in the respiratory and oncology segments. The company has a robust pipeline of products, including inhalers and injectables, which are expected to drive growth in the coming quarters. Additionally, Cipla's partnership with global pharmaceutical companies is expected to provide a boost to its revenue and profitability.

Investment Rationale

The investment rationale for Cipla is based on its strong product pipeline, improving operational efficiency, and partnership with global pharmaceutical companies. The company's valuation is also attractive, with a price-to-earnings (P/E) ratio of 23.5, which is lower than its peers. The brokerages believe that Cipla's stock has the potential to outperform the market in the coming quarters, driven by its strong growth prospects and improving profitability.

Conclusion

In conclusion, Cipla's shares have rallied 8% despite a 55% YoY slump in Q4 profit, driven by the bullish stance of several brokerages. The company's strong product pipeline, improving operational efficiency, and partnership with global pharmaceutical companies are expected to drive growth in the coming quarters. With a target price of ₹1,550-1,600, Cipla's stock is an attractive investment opportunity for investors looking for long-term growth.

The Nifty 50 index closed at 23,471.10, up 58.5 points, while the BSE Sensex closed at 79,565.42, up 221.42 points. The Indian stock market is expected to remain volatile in the coming sessions, driven by global economic trends and corporate earnings. However, Cipla's strong growth prospects and attractive valuation make it an attractive investment opportunity for investors.